The potential of BRD4 inhibition in tumour mechanosignaling.
作者信息
Gargalionis Antonios N, Papavassiliou Kostas A, Papavassiliou Athanasios G
机构信息
Department of Biopathology, 'Eginition' Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
First University Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
J Cell Mol Med. 2023 Dec;27(24):4215-4218. doi: 10.1111/jcmm.18057. Epub 2023 Nov 23.
Abstract
摘要
相似文献
1
The potential of BRD4 inhibition in tumour mechanosignaling.BRD4抑制在肿瘤机械信号传导中的潜力。
J Cell Mol Med. 2023 Dec;27(24):4215-4218. doi: 10.1111/jcmm.18057. Epub 2023 Nov 23.
2
Metabolic control of YAP and TAZ by the mevalonate pathway.甲羟戊酸途径对 YAP 和 TAZ 的代谢调控。
Nat Cell Biol. 2014 Apr;16(4):357-66. doi: 10.1038/ncb2936. Epub 2014 Mar 23.
3
YAP/TAZ as therapeutic targets in cancer.YAP/TAZ作为癌症治疗靶点
Curr Opin Pharmacol. 2016 Aug;29:26-33. doi: 10.1016/j.coph.2016.05.002. Epub 2016 Jun 2.
4
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.通过YAP和TAZ的机械信号传导驱动成纤维细胞活化和纤维化。
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57. doi: 10.1152/ajplung.00300.2014. Epub 2014 Dec 12.
5
Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models.从细胞系统和小鼠模型看 Yap/Taz 的调控
Curr Stem Cell Res Ther. 2018;13(1):16-25. doi: 10.2174/1574888X12666170102124421.
6
The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.SWI/SNF 复合物是 YAP 和 TAZ 的机械调节抑制剂。
Nature. 2018 Nov;563(7730):265-269. doi: 10.1038/s41586-018-0658-1. Epub 2018 Oct 31.
7
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.作为再生医学和癌症治疗靶点的河马信号通路及YAP/TAZ-TEAD蛋白-蛋白相互作用
J Med Chem. 2015 Jun 25;58(12):4857-73. doi: 10.1021/jm501615v. Epub 2015 Mar 11.
8
YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers.YAP 和 TAZ：人类癌症中单绒毛膜和双绒毛膜的转录共激活因子。
Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188756. doi: 10.1016/j.bbcan.2022.188756. Epub 2022 Jun 28.
9
Metabolism: YAP and TAZ under metabolic control.新陈代谢：处于代谢调控下的YAP和TAZ
Nat Rev Mol Cell Biol. 2014 May;15(5):296. doi: 10.1038/nrm3796. Epub 2014 Apr 16.
10
A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.一种YAP/TAZ诱导的反馈机制调节Hippo信号通路的稳态。
Genes Dev. 2015 Jun 15;29(12):1271-84. doi: 10.1101/gad.262816.115.
引用本文的文献
1
Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.同源重组修复缺陷型转移性前列腺癌：新的治疗机会。
Int J Mol Sci. 2024 Apr 24;25(9):4624. doi: 10.3390/ijms25094624.
本文引用的文献
1
Targeting the YAP/TAZ mechanotransducers in solid tumour therapeutics.在实体瘤治疗中靶向YAP/TAZ机械转导蛋白
J Cell Mol Med. 2023 Jul;27(13):1911-1914. doi: 10.1111/jcmm.17794. Epub 2023 May 25.
2
Oncogenic signaling-mediated regulation of chromatin during tumorigenesis.致癌信号在肿瘤发生过程中对染色质的调节。
Cancer Metastasis Rev. 2023 Jun;42(2):409-425. doi: 10.1007/s10555-023-10104-3. Epub 2023 May 6.
3
YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer.YAP/BRD4 调控的 ROR1 促进胰腺癌肿瘤起始细胞和过度增殖。
EMBO J. 2023 Jul 17;42(14):e112614. doi: 10.15252/embj.2022112614. Epub 2023 Apr 25.
4
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.Pelabresib（CPI-0610）治疗复发或难治性淋巴瘤患者的 I 期研究。Pelabresib（CPI-0610）是一种 BET 蛋白小分子抑制剂。
Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug.
5
The YAP-TEAD4 complex promotes tumor lymphangiogenesis by transcriptionally upregulating CCBE1 in colorectal cancer.YAP-TEAD4 复合物通过转录上调结直肠癌中的 CCBE1 促进肿瘤淋巴管生成。
J Biol Chem. 2023 Apr;299(4):103012. doi: 10.1016/j.jbc.2023.103012. Epub 2023 Feb 11.
6
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.一项评估 Molibresib 治疗复发/难治性血液系统恶性肿瘤的 I/II 期开放性研究。
Clin Cancer Res. 2023 Feb 16;29(4):711-722. doi: 10.1158/1078-0432.CCR-22-1284.
7
Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.BRD4 和 YAP 在 GNAQ 突变性葡萄膜黑素瘤细胞中的相互正调控赋予 BET 抑制剂敏感性。
Pharmacol Res. 2022 Oct;184:106464. doi: 10.1016/j.phrs.2022.106464. Epub 2022 Sep 24.
8
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.BMS-986158，一种溴结构域和额外末端结构域蛋白的小分子抑制剂，用于特定晚期实体瘤患者：1/2a期试验结果
Cancers (Basel). 2022 Aug 23;14(17):4079. doi: 10.3390/cancers14174079.
9
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.III期MANIFEST-2研究：在初治的骨髓纤维化患者中，培拉布瑞西布+鲁索替尼对比安慰剂+鲁索替尼
Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.
10
YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.YAP1 在头颈部鳞状细胞癌中维持活跃的染色质状态，通过与 BRD4 合作促进肿瘤发生。
Cell Rep. 2022 Jun 14;39(11):110970. doi: 10.1016/j.celrep.2022.110970.
Zotero 插件